Literature DB >> 1380891

Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product.

A E Ottenhoff-Kalff1, G Rijksen, E A van Beurden, A Hennipman, A A Michels, G E Staal.   

Abstract

Tyrosine phosphorylation is an important regulatory mechanism in response to the action of growth factors and oncogenes. Since many oncogenes code for tyrosine kinases, increased or altered oncogene expression may be reflected in increased tyrosine kinase activity. In a recent study (Hennipman et al., Cancer Res., 49: 516-521, 1989), we found that the tyrosine kinase activity of the cytosolic and membrane fractions of malignant human breast tissue was significantly higher compared to the benign or the normal breast tissue. Moreover, the increase in the cytosolic fractions was found to be of prognostic value. In the present study we determined the protein tyrosine kinase (PTK) activity of another 72 breast cancer specimens, and it could be shown again that the PTK activity in all 72 of these tumors was elevated compared to normal controls. We characterized these cytosolic PTKs by anion exchange chromatography using fast protein liquid chromatography, and it could be shown that at least two different forms of PTK exist. Using antibodies against a number of known oncogene products, we could determine that at least 70% of the PTK activity in the cytosol originated from the presence of the c-src oncogene product. Both of the PTK activity peaks seen in the fast protein liquid chromatography patterns could be precipitated with the anti-Src antibody. Furthermore, using the MCF-7 breast cancer cell line, it could be shown that the antibody against c-src also precipitated a part of the cytosolic PTK activity. In normal human peripheral lymphocytes, no precipitation of the cytosolic and membrane PTK activity could be achieved using the anti-Src antibody. Inasmuch as the cytosolic PTK activity parallels the malignancy in breast tumors (Hennipman et al., Cancer Res., 49: 516-521, 1989), and the majority of this activity is precipitated by anti-Src antibodies, the c-src protooncogene may play a key role in the manifestation of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380891

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  81 in total

1.  Reovirus as a novel oncolytic agent.

Authors:  K L Norman; P W Lee
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Non-transcriptional action of oestradiol and progestin triggers DNA synthesis.

Authors:  G Castoria; M V Barone; M Di Domenico; A Bilancio; D Ametrano; A Migliaccio; F Auricchio
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

3.  Mechanism of biological synergy between cellular Src and epidermal growth factor receptor.

Authors:  D A Tice; J S Biscardi; A L Nickles; S J Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

4.  ZBP1 enhances cell polarity and reduces chemotaxis.

Authors:  Kyle Lapidus; Jeffrey Wyckoff; Ghassan Mouneimne; Mike Lorenz; Lillian Soon; John S Condeelis; Robert H Singer
Journal:  J Cell Sci       Date:  2007-09-15       Impact factor: 5.285

5.  Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.

Authors:  Ting Chen; Changyuan Wang; Qi Liu; Qiang Meng; Huijun Sun; Xiaokui Huo; Pengyuan Sun; Jinyong Peng; Zhihao Liu; Xiaobo Yang; Kexin Liu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 6.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

Review 7.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

8.  Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene.

Authors:  M A Webster; R D Cardiff; W J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

9.  Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers.

Authors:  M C Maa; T H Leu; D J McCarley; R C Schatzman; S J Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

Review 10.  Protein kinases in human breast cancer.

Authors:  W G Cance; E T Liu
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.